The role and efficacy of Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

The active substances in Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf), pertuzumab and trastuzumab, are monoclonal antibodies (a type of protein) designed to attach to HER2. HER2 is a protein on cancer cells that makes tumor cells grow faster and is present in large amounts in about a quarter of breast cancers. By connecting to HER2, pertuzumab and trastuzumab prevent HER2 from producing signals that cause cancer cells to grow. They also activate cells of the immune system (the body's natural defense), which then kill cancer cells. Pertuzumab and trastuzumab attach to two different parts of HER2, and their actions have complementary effects. These combined effects slow cancer growth.

Pertuzumab and trastuzumabgiven by intravenous infusion have been authorized together to treatHER2-positive breast cancer. A major study of 500 patients showed that subcutaneous injection of Phesgo was as effective as this combination. The study showed that pertuzumab and trastuzumab levels were similar in the blood of patients who received Phesgo and those who received the combination via infusion. Additionally, about 60% of patients in both groups (150 of 252 in the Phesgo group and 148 of 248 in the Pertuzumab and trastuzumab groups) had no signs of cancer in the breast and armpit glands after one year of treatment.

The original Phesgo drug is not marketed in the country and therefore cannot be included in medical insurance. Since Phesgo's original drug has been on the market overseas for a short time, there is less price and other related information. For specific prices and drug information, please consult Yaode's medical consultant.